NCT00486408View on ClinicalTrials.gov

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2012

Conditions
HIV Infections
Interventions
BIOLOGICAL

MRKAd5 HIV-1 gag/pol/nef

1.5x10\^10 Ad vg

Trial Locations (4)

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

35294

Alabama Vaccine CRS, Birmingham

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00486408 - Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults | Biotech Hunter | Biotech Hunter